Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.57 |
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 8/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7023449 | 0.90 | MAPT (0.72) | ALDH1A1RAB9AMAPTNPC1KMT2A | |
| SCHEMBL3491508 | 0.86 | GRM6 (0.59) | ALDH1A1RAB9AMAPTNPC1KMT2A | |
| SCHEMBL20154271 | 0.82 | RAB9A (0.59) | ALDH1A1RAB9AMAPTNPC1KMT2A | |
| SCHEMBL3490918 | 0.80 | ALDH1A1 (0.59) | ALDH1A1RAB9AMAPTNPC1KMT2A | |
| SCHEMBL13636678 | 0.79 | RAB9A (0.48) | ALDH1A1RAB9AMAPTNPC1KMT2A | |
| SCHEMBL8042616 | 0.78 | ALDH1A1 (0.59) | ALDH1A1RAB9AMAPTNPC1KMT2A | |
| SCHEMBL8058314 | 0.77 | ALDH1A1 (0.55) | ALDH1A1RAB9AMAPTKMT2AMEN1 | |
| SCHEMBL3322377 | 0.77 | ALDH1A1 (0.69) | ALDH1A1RAB9AMAPTNPC1KMT2A | |
| SCHEMBL20154269 | 0.76 | RAB9A (0.53) | ALDH1A1RAB9AMAPTNPC1KMT2A | |
| SCHEMBL20711150 | 0.76 | RAB9A (0.53) | ALDH1A1RAB9AMAPTNPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064122-B2 | Pancreatic lipase inhibitor compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1467978-A4 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1467978-A1 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030195199-A1 | Pancreatic lipase inhibitor compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003053944-A1 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| US-6037340-A | HAVE BIOLOGICAL ACTIVITY INCLUDING ANTI-CANCER ACTIVITY | CADUS PHARMACEUTICAL CORPORATION (US) | 2000-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195199-A1 | Pancreatic lipase inhibitor compounds, their synthesis and use | PNLIP, LIPC, CEL | ALDH1A1 1832/4885RAB9A 3221/4885MAPT 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.